Induction of Autophagy Is an Early Response to Gefitinib and a Potential Therapeutic Target in Breast Cancer

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Dragowska, Wieslawa H ^a   Weppler, Sherry A ^a   Wang, Jun Chih ^a   Wong, Ling Yan ^a   Kapanen, Anita I ^a   Rawji, Jenna S ^a   Warburton, Corinna ^a   Qadir, Mohammed A ^a   Donohue, Elizabeth ^b   Roberge, Michel ^b,c   Gorski, Sharon M ^a,d   Gelmon, Karen A ^a,b   Bally, Marcel B ^a,b,c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Center for Drug Research and Development   (Canada)

^d SIMON FRASER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BAFILOMYCIN A1; BECLIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; HYDROXYCHLOROQUINE; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA;

ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; BREAST CANCER; CANCER CELL; CELL DEATH; CLONOGENIC ASSAY; DOWN REGULATION; DRUG TARGETING; FLOW CYTOMETRY; HUMAN; MONOTHERAPY; PHENOTYPE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING;

ADENINE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BREAST NEOPLASMS; CADAVERINE; CELL LINE, TUMOR; CELL SURVIVAL; CYTOPLASMIC VESICLES; FEMALE; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; HYDROXYCHLOROQUINE; MEMBRANE PROTEINS; MICE; PHAGOSOMES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAINING AND LABELING; TAMOXIFEN; TREATMENT OUTCOME; UBIQUITIN-ACTIVATING ENZYMES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885412828     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076503     Document Type: Article

References (65)

1. Wiseman SM, Makretsov N, Nielsen TO, Gilks B, Yorida E, et al. (2005) Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer 103: 1770-1777. doi:10.1002/cncr.20970. PubMed: 15770691.
2. DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D 2nd, et al. (2005) Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 23: 1152-1160. doi:10.1200/JCO.2005.09.055. PubMed: 15718311.
3. Rimawi MF, Shetty PB, Weiss HL, Schiff R, Osborne CK, et al. (2010) Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer 116: 1234-1242. doi:10.1002/cncr.24816. PubMed: 20082448.
4. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, et al. (2007) Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13: 4909-4919. doi:10.1158/1078-0432.CCR-07-0701. PubMed: 17699871.
5. Saxena R, Dwivedi A, (2012) ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective. Med Res Rev 32: 166-215. doi:10.1002/med.20209. PubMed: 22183797.
6. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD Jr., et al. (2004) United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 10: 1212-1218. doi:10.1158/1078-0432.CCR-03-0564. PubMed: 14977817.
7. Moasser MM, Basso A, Averbuch SD, Rosen N, (2001) The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61: 7184-7188. PubMed: 11585753.
8. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, et al. (2001) Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61: 8887-8895. PubMed: 11751413.
9. Warburton C, Dragowska WH, Gelmon K, Chia S, Yan H, et al. (2004) Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin Cancer Res 10: 2512-2524. doi:10.1158/1078-0432.CCR-03-0244. PubMed: 15073131.
10. Anido J, Matar P, Albanell J, Guzmán M, Rojo F, et al. (2003) ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9: 1274-1283. PubMed: 12684395.
11. Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, et al. (2005) Cellular targets of gefitinib. Cancer Res 65: 379-382. PubMed: 15695376.
12. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G, (2007) Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 8: 741-752. doi:10.1038/nrm2239. PubMed: 17717517.
13. Bampton ET, Goemans CG, Niranjan D, Mizushima N, Tolkovsky AM, (2005) The dynamics of autophagy visualized in live cells: from autophagosome formation to fusion with endo/lysosomes. Autophagy 1: 23-36. PubMed: 16874023.
14. Abedin MJ, Wang D, McDonnell MA, Lehmann U, Kelekar A, (2007) Autophagy delays apoptotic death in breast cancer cells following DNA damage. Cell Death Differ 14: 500-510. doi:10.1038/sj.cdd.4402039. PubMed: 16990848.
15. Qadir MA, Kwok B, Dragowska WH, To KH, Le D, et al. (2008) Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization. Breast Cancer Res Treat 112: 389-403. doi:10.1007/s10549-007-9873-4. PubMed: 18172760.
16. Takeuchi H, Kanzawa T, Kondo Y, Kondo S, (2004) Inhibition of platelet-derived growth factor signalling induces autophagy in malignant glioma cells. Br J Cancer 90: 1069-1075. doi:10.1038/sj.bjc.6601605. PubMed: 14997209.
17. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA, (2009) Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. PLOS ONE 4: e6251. doi:10.1371/journal.pone.0006251. PubMed: 19606230.
18. Han W, Pan H, Chen Y, Sun J, Wang Y, et al. (2011) EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLOS ONE 6: e18691. doi:10.1371/journal.pone.0018691. PubMed: 21655094.
19. Chen S, Li X, Feng J, Chang Y, Wang Z, et al. (2011) Autophagy facilitates the Lapatinib resistance of HER2 positive breast cancer cells. Med Hypotheses 77: 206-208. doi:10.1016/j.mehy.2011.04.013. PubMed: 21570197.
20. Harhaji-Trajkovic L, Vilimanovich U, Kravic-Stevovic T, Bumbasirevic V, Trajkovic V, (2009) AMPK-mediated autophagy inhibits apoptosis in cisplatin-treated tumour cells. J Cell Mol Med 13: 3644-3654. doi:10.1111/j.1582-4934.2009.00663.x. PubMed: 20196784.
21. Li X, Lu Y, Pan T, Fan Z, (2010) Roles of autophagy in cetuximab-mediated cancer therapy against EGFR. Autophagy 6: 1066-1077. doi:10.4161/auto.6.8.13366. PubMed: 20864811.
22. Sun WL, Chen J, Wang YP, Zheng H, (2011) Autophagy protects breast cancer cells from epirubicin-induced apoptosis and facilitates epirubicin-resistance development. Autophagy 7: 1035-1044. doi:10.4161/auto.7.9.16521. PubMed: 21646864.
23. Apel A, Herr I, Schwarz H, Rodemann HP, Mayer A, (2008) Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer Res 68: 1485-1494. doi:10.1158/0008-5472.CAN-07-0562. PubMed: 18316613.
24. Degtyarev M, De Mazière A, Orr C, Lin J, Lee BB, et al. (2008) Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol 183: 101-116. doi:10.1083/jcb.200801099. PubMed: 18838554.
25. Gupta A, Roy S, Lazar AJ, Wang WL, McAuliffe JC, et al. (2010) Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST). Proc Natl Acad Sci U S A 107: 14333-14338. doi:10.1073/pnas.1000248107. PubMed: 20660757.
26. Mirzoeva OK, Hann B, Hom YK, Debnath J, Aftab D, et al. (2011) Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma. J Mol Med (Berl) 89: 877-889. doi:10.1007/s00109-011-0774-y. PubMed: 21678117.
27. Ma XH, Piao S, Wang D, McAfee QW, Nathanson KL, et al. (2011) Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. Clin Cancer Res 17: 3478-3489. doi:10.1158/1078-0432.CCR-10-2372. PubMed: 21325076.
28. Hu YL, Jahangiri A, Delay M, Aghi MK, (2012) Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy. Cancer Res 72: 4294-4299. doi:10.1158/1538-7445.AM2012-4294. PubMed: 22915758.
29. Janku F, McConkey DJ, Hong DS, Kurzrock R, (2011) Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol 8: 528-539. doi:10.1038/nrclinonc.2011.71. PubMed: 21587219.
30. Maycotte P, Thorburn A, (2011) Autophagy and cancer therapy. Cancer Biol Ther 11: 127-137. doi:10.4161/cbt.11.2.14627. PubMed: 21178393.
31. Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, et al. (2011) Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 17: 654-666. doi:10.1158/1078-0432.CCR-10-2634. PubMed: 21325294.
32. Swampillai AL, Salomoni P, Short SC, (2012) The role of autophagy in clinical practice. Clin Oncol R Coll Radiol 24: 387-395. doi:10.1016/j.clon.2011.09.010. PubMed: 22032864.
33. Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, et al. (2004) Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 3: 1585-1592. PubMed: 15634652.
34. Balgi AD, Fonseca BD, Donohue E, Tsang TC, Lajoie P, et al. (2009) Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLOS ONE 4: e7124. doi:10.1371/journal.pone.0007124. PubMed: 19771169.
35. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, et al. (2012) Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8: 445-544. doi:10.4161/auto.19496. PubMed: 22966490.
36. Dragowska WH, Weppler SA, Qadir MA, Wong LY, Franssen Y, et al. (2011) The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity. BMC Cancer 11: 420. doi:10.1186/1471-2407-11-420. PubMed: 21961653.
37. Weigelt B, Warne PH, Downward J, (2011) PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene.
38. Köninki K, Barok M, Tanner M, Staff S, Pitkänen J, et al. (2010) Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. Cancer Lett 294: 211-219. doi:10.1016/j.canlet.2010.02.002. PubMed: 20193978.
39. McKillop D, Partridge EA, Kemp JV, Spence MP, Kendrew J, et al. (2005) Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol Cancer Ther 4: 641-649. doi:10.1158/1535-7163.MCT-04-0329. PubMed: 15827338.
40. Yoshimori T, Yamamoto A, Moriyama Y, Futai M, Tashiro Y, (1991) Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J Biol Chem 266: 17707-17712. PubMed: 1832676.
41. Wirawan E, Lippens S, Vanden Berghe T, Romagnoli A, Fimia GM, et al. (2012) Beclin1: a role in membrane dynamics and beyond. Autophagy 8: 6-17. doi:10.4161/auto.8.1.16645. PubMed: 22170155.
42. Kaiser SE, Mao K, Taherbhoy AM, Yu S, Olszewski JL, et al. (2012) Noncanonical E2 recruitment by the autophagy E1 revealed by Atg7-Atg3 and Atg7-Atg10 structures. Nat Struct Mol Biol 19: 1242-1249. doi:10.1038/nsmb.2415. PubMed: 23142976.
43. Cooper RG, Magwere T, (2008) Chloroquine: novel uses & manifestations. Indian J Med Res 127: 305-316. PubMed: 18577785.
44. Swaisland HC, Smith RP, Laight A, Kerr DJ, Ranson M, et al. (2005) Single-dose clinical pharmacokinetic studies of gefitinib. Clin Pharmacokinet 44: 1165-1177. doi:10.2165/00003088-200544110-00004. PubMed: 16231967.
45. Jahanzeb M, (2008) Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer 8: 324-333. doi:10.3816/CBC.2008.n.037. PubMed: 18757259.
46. Tevaarwerk AJ, Kolesar JM, (2009) Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther 312:: 2332-2348. PubMed: 20110044.
47. Gelmon KA, Mackey J, Verma S, Gertler SZ, Bangemann N, et al. (2004) Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 5: 52-62; discussion: 15140285.
48. Nahta R, Esteva FJ, (2007) Trastuzumab: triumphs and tribulations. Oncogene 26: 3637-3643. doi:10.1038/sj.onc.1210379. PubMed: 17530017.
49. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, et al. (2012) Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 9: 16-32. PubMed: 22124364.
50. Rexer BN, Arteaga CL, (2012) Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog 17: 1-16. doi:10.1615/CritRevOncog.v17.i1.20. PubMed: 22471661.
51. Bernardini M, Lee CH, Beheshti B, Prasad M, Albert M, et al. (2005) High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia 7: 603-613. doi:10.1593/neo.04760. PubMed: 16036111.
52. Prasad M, Bernardini M, Tsalenko A, Marrano P, Paderova J, et al. (2008) High definition cytogenetics and oligonucleotide aCGH analyses of cisplatin-resistant ovarian cancer cells. Genes Chromosomes Cancer 47: 427-436. doi:10.1002/gcc.20547. PubMed: 18273836.
53. Lipinski MM, Hoffman G, Ng A, Zhou W, Py BF, et al. (2010) A genome-wide siRNA screen reveals multiple mTORC1 independent signaling pathways regulating autophagy under normal nutritional conditions. Dev Cell 18: 1041-1052. doi:10.1016/j.devcel.2010.05.005. PubMed: 20627085.
54. Zou Y, Ling YH, Sironi J, Schwartz EL, Perez-Soler R, et al. (2013) The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib. J Thorac Oncol 8: 693-702. doi:10.1097/JTO.0b013e31828c7210. PubMed: 23575415.
55. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, et al. (2008) Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13: 385-393. doi:10.1016/j.ccr.2008.03.015. PubMed: 18455122.
56. Zhang L, Gjoerup O, Roberts TM, (2004) The serine/threonine kinase cyclin G-associated kinase regulates epidermal growth factor receptor signaling. Proc Natl Acad Sci U S A 101: 10296-10301. doi:10.1073/pnas.0403175101. PubMed: 15240878.
57. Eisenberg-Lerner A, Bialik S, Simon HU, Kimchi A, (2009) Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ 16: 966-975. doi:10.1038/cdd.2009.33. PubMed: 19325568.
58. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, et al. (2004) Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 11: 448-457. doi:10.1038/sj.cdd.4401359. PubMed: 14713959.
59. Shingu T, Fujiwara K, Bögler O, Akiyama Y, Moritake K, et al. (2009) Inhibition of autophagy at a late stage enhances imatinib-induced cytotoxicity in human malignant glioma cells. Int J Cancer 124: 1060-1071. doi:10.1002/ijc.24030. PubMed: 19048625.
60. Maycotte P, Aryal S, Cummings CT, Thorburn J, Morgan MJ, et al. (2012) Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. Autophagy 8: 200-212. doi:10.4161/auto.8.2.18554. PubMed: 22252008.
61. Boya P, Gonzalez-Polo RA, Poncet D, Andreau K, Vieira HL, et al. (2003) Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene 22: 3927-3936. doi:10.1038/sj.onc.1206622. PubMed: 12813466.
62. Bristol ML, Emery SM, Maycotte P, Thorburn A, Chakradeo S, et al. (2013) Autophagy inhibition for chemosensitization and radiosensitization in cancer: do the preclinical data support this therapeutic strategy? J Pharmacol Exp Ther, 344: 544-52. PubMed: 23291713.
63. Lamoureux F, Thomas C, Crafter C, Kumano M, Zhang F, et al. (2013) Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363. Clin Cancer Res 19: 833-844. doi:10.1158/1078-0432.CCR-12-3114. PubMed: 23258740.
64. Aita VM, Liang XH, Murty VV, Pincus DL, Yu W, et al. (1999) Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics 59: 59-65. doi:10.1006/geno.1999.5851. PubMed: 10395800.
65. Saito H, Inazawa J, Saito S, Kasumi F, Koi S, et al. (1993) Detailed deletion mapping of chromosome 17q in ovarian and breast cancers: 2-cM region on 17q21.3 often and commonly deleted in tumors. Cancer Res 53: 3382-3385. PubMed: 8100738.